TMEM107

Across TCGA pan-cancer cohorts, TMEM107 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM107 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM107 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM107 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUAD, UCEC, and LGG are the cancer types where TMEM107 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.163	0.835	<.001	30	view →
UCEC	DFS	Median	II,III,IV	1.000	0.438	.020	26	view →
LGG	OS	Median	All	0.128	0.811	<.001	12	view →
PRAD	DFS	Median	All	0.068	0.935	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	OS	Median	II,III,IV	1.000	0.701	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM107–LUAD (OS)

Open the LUAD breakdown →